Despite frequently encountered situation, the entire picture of molecular basis on hypercalcemia is not necessarily understood widely. In this issue, Dr. Noriko Makita and colleague at the University of Tokyo, world-renowned cutting-edge scientists on hypercalcemia, contribute a well-organized and sophisticated review article of primary hyperparathyroidism (PHPT), familial hypocalciuric hypercalcemia (FHH), and acquired hypocalciuric hypercalcemia (AHH) caused by blocking antibodies against the calcium sensing receptor (CaSR). We are sure that readers will be fascinated by the updated, profound world of calcium handling and dysmetabolism.
Recommendation from the Editor in Chief
Despite frequently encountered situation, the entire picture of molecular basis on hypercalcemia is not necessarily understood widely. In this issue, Dr. Noriko Makita and colleague at the University of Tokyo, world-renowned cutting-edge scientists on hypercalcemia, contribute a well-organized and sophisticated review article of primary hyperparathyroidism (PHPT), familial hypocalciuric hypercalcemia (FHH), and acquired hypocalciuric hypercalcemia (AHH) caused by blocking antibodies against the calcium sensing receptor (CaSR). We are sure that readers will be fascinated by the updated, profound world of calcium handling and dysmetabolism.